Parabilis Medicines cannot currently be evaluated on price-based measures due to a missing price feed, and the available fundamentals point to margin compression, insider selling, and below-average quality that argue for caution once trading data is restored.
Thesis pillars
- Value Trap Signals Margin And Insider Selling↓Deteriorating
- Data Outage Blocks Trade Setup↓Deteriorating
- Quality Concerns Flagged→Stable
- +2 more pillars — see the Why tab for full reasoning
Parabilis Medicines, Inc. (PBLS) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $40.11: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: Elevated put/call ratio: 2.40; Below-average business quality; Rich valuation.
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that... Read more
Sell if holding. Engine safety override at $40.11: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: Elevated put/call ratio: 2.40; Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.4/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 70d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: speculative.
Recent developments
updated 2026-09-03Recent Developments — Parabilis Medicines, Inc.
Latest news
- NEWS Parabilis Medicines Q2 EPS $(2.32) Misses $(0.08) Estimate, Sales $148.000K Miss $25.000M Estimate — benzinga Aug 13, 2026 negative
- NEWS Leerink Partners Initiates Coverage On Parabilis Medicines with Outperform Rating, Announces Price Target of $40 — benzinga Jul 6, 2026 positive
- NEWS This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday — benzinga Jul 6, 2026 positive
- NEWS B of A Securities Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $45 — benzinga Jul 6, 2026 positive
Generated 2026-09-03T14:22:18Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $40.11: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: Elevated put/call ratio: 2.40; Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $37.30. Score 4.4/10, moderate confidence.
Take-profit target: $46.13 (-11.5% upside). Prior stop was $37.30. Stop-loss: $37.30.
Target reached (-11.5% upside); Quality below floor (3.0 < 4.0).
Parabilis Medicines, Inc. trades at a P/E of N/A (forward -18.1). TrendMatrix value score: 3.0/10. Verdict: Sell.
11 analysts cover PBLS with a consensus score of 4.4/5. Average price target: $42.
What does Parabilis Medicines, Inc. do?Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide...
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.